Restructuring events
European Restructuring Monitor (ERM)
The restructuring events database contains factsheets with data on large-scale restructuring events reported in the principal national media and company websites in each EU Member State. This database was created in 2002.
Catalent UK, the British subsidiary of the US-based global pharmaceutical company, has confirmed that it will close its plant in Bolton, Greater Manchester, in the north west of England, over the next nine months. The closure will make 150 jobs redundant, which will be relocated to the company sites in the US, Germany and Bathgate, Scotland.
A representative of the company said the decision about the planned closure was made after reviewing the demand for clinical trial supply services in the UK.
A representative of the trade union Unite said the closure was due to the UK leaving the European Union and added that the job loss was a ‘blow’ to the employees and the local economy.
Catalent develops and manufactures drugs, gene therapies and consumer health products. It employs more than 14,000 people globally. The company currently has five sites across England and Scotland, with the Bolton site specialising in clinical trial supplies.
Eurofound (2021), Catalent, Offshoring/Delocalisation in United Kingdom, factsheet number 103198, European Restructuring Monitor. Dublin, https://apps.eurofound.europa.eu/restructuring-events/detail/103198.